EntryPoint Capital’s Boston Scientific BSX Stock Holding History

EntryPoint Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$339K	Sell	5,405 -2,643	-33%	-$211K	0.1%	418
2025 Q4	$767K	Buy	+8,048	New	+$789K	0.3%	61
2024 Q1	–	Sell	-165	Closed	-$9.54K	–	1445
2023 Q4	$9.54K	Buy	+165	New	+$8.81K	0.01%	1159

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EntryPoint Capital's BSX Position: Q1 2026 in Review

EntryPoint Capital reduced its Boston Scientific (BSX) stake by 33% in Q1 2026, selling an estimated $211K and leaving 5,405 shares worth $339K. The position accounts for 0.1% of the portfolio, ranked #418.

EntryPoint Capital first reported a position in BSX in Q4 2023 and has held it in 3 quarters since. The position peaked at $767K in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

EntryPoint Capital held 5,405 shares of Boston Scientific worth $339K as of Q1 2026.
EntryPoint Capital sold 2,643 Boston Scientific shares in Q1 2026, an estimated $211K.
Boston Scientific made up 0.1% of EntryPoint Capital's portfolio in Q1 2026, its #418 holding.
EntryPoint Capital first reported a position in Boston Scientific in Q4 2023 and has held it in 3 quarters since.
EntryPoint Capital's Boston Scientific position peaked at $767K in Q4 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.